Int J Cardiol: 医疗保险制度完善,服药依从性越好

2017-03-22 MedSci MedSci原创

背景:缺乏医疗保险可能对服药依从性及心血管危险因素的控制产生不利影响。研究者调查保险和LDL-C之间的相关性是否因为自我服药依从性低。方法:本研究包括脑卒中地理和种族差异的原因(REGARDS)队列研究中,8685例45岁以上的黑人和白人男性和女性,这些患者使用他汀类药物。应用MMAS-4评估服药依从性。校正MMSA-4前后,应用广义线性模型计算有无保险的受试者,LDL-C的差异。按年龄分层,家庭

背景:缺乏医疗保险可能对服药依从性及血管危险因素的控制产生不利影响。研究者调查医疗保险和LDL-C之间的相关性是否因为自我服药依从性低?

方法:本研究包括脑卒中地理和种族差异原因(REGARDS)队列研究中,8685例45岁以上使用他汀类药物患者,这些患者有黑人和白人,男性和女性。应用MMAS-4评估服药依从性。校正MMSA-4前后,应用广义线性模型计算有无医疗保险受试者的LDL-C的差异。按年龄,家庭年收入水平、糖尿病及冠心病分层。另外,对MMAS-4单独进行分析确定是否存在中介效应。

结果:多变量调整,未对MMAS-4时,无保险者的受试者LDL-C高于有保险的受试者2.5mg/dl(95% CI 0.6,5.6)。对MMAS-4进一步校正后,无保险者受试者的LDL-C高于有保险者2.6mg/dl(95% CI 0.5,5.6)。分层分析后,结果一致。对每个MMAS-4单独分析未发现中介作用。

结论:高服药依从性对健康保险和降低LDL-C的关系没有影响。

原文出处:

Mefford M, Safford MM,et al. Insurance, self-reported medication adherence and LDL cholesterol: The REasons for Geographic And Racial Differences in Stroke study. Int J Cardiol. 2017 Feb 22.


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1781738, encodeId=eecd1e81738f5, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jun 15 17:44:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319266, encodeId=743a131926632, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Fri Mar 24 01:44:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369680, encodeId=0c13136968068, content=<a href='/topic/show?id=57b53481e9f' target=_blank style='color:#2F92EE;'>#医疗保险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34817, encryptionId=57b53481e9f, topicName=医疗保险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Fri Mar 24 01:44:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599516, encodeId=838a159951628, content=<a href='/topic/show?id=31992e25482' target=_blank style='color:#2F92EE;'>#保险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27254, encryptionId=31992e25482, topicName=保险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db9918732976, createdName=feifers, createdTime=Fri Mar 24 01:44:00 CST 2017, time=2017-03-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1781738, encodeId=eecd1e81738f5, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jun 15 17:44:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319266, encodeId=743a131926632, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Fri Mar 24 01:44:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369680, encodeId=0c13136968068, content=<a href='/topic/show?id=57b53481e9f' target=_blank style='color:#2F92EE;'>#医疗保险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34817, encryptionId=57b53481e9f, topicName=医疗保险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Fri Mar 24 01:44:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599516, encodeId=838a159951628, content=<a href='/topic/show?id=31992e25482' target=_blank style='color:#2F92EE;'>#保险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27254, encryptionId=31992e25482, topicName=保险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db9918732976, createdName=feifers, createdTime=Fri Mar 24 01:44:00 CST 2017, time=2017-03-24, status=1, ipAttribution=)]
    2017-03-24 fyxzlh
  3. [GetPortalCommentsPageByObjectIdResponse(id=1781738, encodeId=eecd1e81738f5, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jun 15 17:44:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319266, encodeId=743a131926632, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Fri Mar 24 01:44:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369680, encodeId=0c13136968068, content=<a href='/topic/show?id=57b53481e9f' target=_blank style='color:#2F92EE;'>#医疗保险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34817, encryptionId=57b53481e9f, topicName=医疗保险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Fri Mar 24 01:44:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599516, encodeId=838a159951628, content=<a href='/topic/show?id=31992e25482' target=_blank style='color:#2F92EE;'>#保险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27254, encryptionId=31992e25482, topicName=保险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db9918732976, createdName=feifers, createdTime=Fri Mar 24 01:44:00 CST 2017, time=2017-03-24, status=1, ipAttribution=)]
    2017-03-24 xuyu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1781738, encodeId=eecd1e81738f5, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jun 15 17:44:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319266, encodeId=743a131926632, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Fri Mar 24 01:44:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369680, encodeId=0c13136968068, content=<a href='/topic/show?id=57b53481e9f' target=_blank style='color:#2F92EE;'>#医疗保险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34817, encryptionId=57b53481e9f, topicName=医疗保险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Fri Mar 24 01:44:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599516, encodeId=838a159951628, content=<a href='/topic/show?id=31992e25482' target=_blank style='color:#2F92EE;'>#保险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27254, encryptionId=31992e25482, topicName=保险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db9918732976, createdName=feifers, createdTime=Fri Mar 24 01:44:00 CST 2017, time=2017-03-24, status=1, ipAttribution=)]
    2017-03-24 feifers

相关资讯

FDA批准新型胆固醇药物(PCSK9抑制剂)

美国FDA近日批准了新型降胆固醇药物。赛诺菲公司的Praulent (alirocumab)获得了FDA的批准,此外安进公司的Repatha(evolocumab)将在8月27日得到FDA的最终决议。这两种注射用药物都是PCSK9抑制剂,而且FDA为这两种药物开了绿灯。这两种药物都是用于降低低密度脂蛋白(通常被称作坏的LDL胆固醇)。通过抑制PCSK9,调节机体的胆固醇水平。现在用于治疗高胆固醇的

PLoS One:护士领导的、电话随访的卒中后血压和LDL-C的二级预防更有效

背景:为了坚持控制血压(BP)和低密度脂蛋白(LDL-C)的水平,卒中或短暂性脑缺血发作后(TIA)加强二级预防的随访是必要的。研究者调查了护士领导,电话随访的方式是否比一般的护理在出院12月后BP和LDL-C水平的控制更有效。 方法:研究者将537名患者随机进行,护士领导,电话随访的方式(干预组)或一般护理(对照组)。在出院后1个月(基线)和12月对患者进行血压和LDL-C的检测。为了达到治疗目

Circulation: 应用他汀药物后,血脂和冠心病发生风险之间的相关性减弱

背景:2001年胆固醇治疗指南发表后,US冠心病成人中他汀类药物的应用增加。方法:研究者收集REGARDS研究中的9578名受试者及KPSC中346 595人,2003年到2007年间的血脂水平,评估血脂和CHD之间的相关性。研究者也收集了1987到1989 ARIC研究中14 590名受试者的血脂水平,对其进行相同的分析。分析限制在45到64岁间,没有CHD,也没有服用他汀类药物的黑人和白人。基

JAMA Intern Med:心脏病患者,低密度脂蛋白水平并不是越低越好

背景:国际指南推荐患有缺血性心脏病的患者进行他汀类药物治疗预防心血管事件的发生,但他汀治疗的目标低密度脂蛋白胆固醇(LDL-C)值不同。这个问题相关的试验数据不确定,缺乏观测数据。目的:评估缺血性心脏病患者应用他汀治疗的LDL-C水平与心血管事件发生的相关性。设计、设置和参与者:这项研究是基于人口的观察性队列研究,从2009年到2013年,应用来自以色列的医疗保健机构数据,这个机构超过430万名成

Int J Cardiol:LDL-C和非HDL-C水平与缺血性卒中风险增加显著相关

背景:血脂水平与脑卒中发病率之间的相关性关系低于血脂水平和冠心病(CHD)的相关性。目的:评估总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)和甘油三酯水平的地理、种族和民族差异是否与卒中事件的发生相关。方法:从卒中的地理和种族差异的原因研究(REGARDS)中,研究者评估基线无卒中的受试者的LDL-C,HCL-C,TC, non-HDL-C(total- HD

低密度脂蛋白计算公式

低密度脂蛋白计算公式